Autolus
Manufacturing · United Kingdom · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
191 Wood White City Ln, London, Greater ...Phone Number
+44 2038296230Website
www.autolus.comRevenue
$92.6 MillionStock Symbol
AUTLIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Autolus
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company headquartered in London, United Kingdom, founded in 2014. The company is focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus engineers precisely targeted, controlled, and highly active T cell therapies designed to better recognize target cells, break down their defense mechanisms, and eliminate them. The company's lead marketed therapy, AUCATZYL (obecabtagene autoleucel, obe-cel), is an FDA-approved CD19-directed CAR T cell therapy indicated for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, and has also received regulatory acceptance for review in Europe. Beyond its approved product, Autolus maintains a pipeline of product candidates in development across hematological malignancies, solid tumors, anRead more
Autolus Org Chart
Get the full picture
Sign in to uncover key details.
JS
Director, Revenue Accounting
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Autolus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Autolus recently announced quarterly report
Funding: Get notified immidiatlly once Autolus has new funding data
Check if Autolus has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Autolus
Click to see if Autolus had a recent Job posting/layoffs
Autolus, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Autolus is spiking on competitors!
Product Launch: Get notified when Autolus launches new products
Recommended Actions
Find VP level buyers at Autolus
Find 3 more new buyers
Compare Similar Companies to Autolus
Compare insights from companies similar to Autolus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$65.1M
501-1,000
Public
$485.9M
2008
MS
Mark StielowVice President, Manufacturing & Technical Operations (US)
Company Profile Activity
Activity Insights
Autolus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Autolus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Autolus.
Autolus financials insights
Gather financial insights about Autolus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series B
$54.3M
2021
Share Placement
$100M
Private Equity
$250M
Autolus Tech Stack
A closer look at the technologies used by Autolus
Most Recent Scoops
Person-Based
Events
Open Position
Person-Based
Events
Open Position
Person-Based
Events
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Autolus
Sign Up For FreeTo access detailed company insights
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company headquartered in London, United Kingdom, founded in 2014. The company is focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell p... Read More
